Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) AI Stock Analysis

0 Followers

Beijing Biostar Pharmaceuticals Co., Ltd. Class H

(HKEX:2563)

Select Model

Rating:57Neutral

Price Target:HKD 3.50▲(0.00% Upside)

Action:reiterated

Date:10/01/26

The overall score is held down by weak fundamentals, including sharp revenue decline, persistent operating and net losses, and ongoing negative cash flow that together point to a challenging and cash-intensive business profile, despite support from a strong, low-leverage balance sheet. Technical indicators provide some offset, as the stock is in an established uptrend, though momentum looks stretched and vulnerable to a pullback. Valuation contributes modestly to the downside, with negative earnings and no dividend offering limited current value and leaving the investment thesis dependent on future execution.

Positive Factors

Low financial leverageExtremely low leverage limits solvency pressure and reduces the burden of interest and refinancing obligations. This gives the company greater financial flexibility than a highly indebted peer while it works to stabilize operations, although it does not by itself resolve cash burn or losses.

Negative Factors

Sharp revenue contractionThe sharp 2025 revenue decline demonstrates an unstable top-line trajectory and weakens the visibility of the company’s commercial base. Sustained contraction would reduce operating absorption, limit reinvestment capacity, and make it harder for the high gross margin to translate into durable earnings.

Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 846.02M
Dividend Yield: ―
Average Volume (3M): 29.13K
Price to Earnings (P/E): -10.2
Beta (1Y): 0.24
Revenue Growth: ―
EPS Growth: ―
Country: Hong Kong
Employees: 134
Sector: General
Sector Strength: 55
Industry: Biotechnology

Beijing Biostar Pharmaceuticals Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Beijing Biostar Pharms Co Ltd focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the U...

Beijing Biostar Pharmaceuticals Co., Ltd. Class H Financial Statement Overview

Summary

Financial performance is mixed: the company benefits from a strong, low-leverage balance sheet with substantial equity and assets, but this is offset by sharply falling revenue, large operating and net losses, and consistently negative operating and free cash flow indicating ongoing cash burn.

Income Statement

22Negative

Balance Sheet

74Positive

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Jun 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	64.58M	37.12M	77.92M	73.75M	37.38M	106.74M
Gross Profit	59.71M	33.65M	66.75M	51.83M	27.20M	100.48M
EBITDA	-105.53M	-139.77M	-173.84M	-198.08M	-170.77M	-430.65M
Net Income	-124.61M	-142.54M	-155.89M	-209.90M	-182.81M	-417.79M
Balance Sheet
Total Assets	855.87M	861.37M	971.51M	854.83M	1.06B	1.45B
Cash, Cash Equivalents and Short-Term Investments	516.22M	508.15M	609.16M	637.54M	830.57M	988.06M
Total Debt	1.61M	2.20M	1.26M	995.01K	2.17M	1.72M
Total Liabilities	116.80M	120.36M	130.31M	54.44M	66.53M	30.34M
Stockholders Equity	739.07M	741.01M	841.20M	800.40M	988.49M	1.42B
Cash Flow
Free Cash Flow	-67.06M	-174.59M	-163.18M	-197.69M	-127.69M	-134.93M
Operating Cash Flow	-63.63M	-168.56M	-119.77M	-166.88M	-90.47M	-118.32M
Investing Cash Flow	-14.74M	99.59M	56.88M	145.30M	-167.18M	192.93M
Financing Cash Flow	-1.52M	-1.39M	221.38M	-1.25M	4.02M	-1.21M

Beijing Biostar Pharmaceuticals Co., Ltd. Class H Technical Analysis

Technical Analysis SentimentNegative

Last Price3.50

Price Trends

50DMA4.02Negative

100DMA3.76Negative

200DMA3.80Negative

Market Momentum

MACD-0.17Positive

RSI35.55Neutral

STOCH33.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2563, the sentiment is Negative. The current price of 3.50 is below the 20-day moving average (MA) of 3.83, below the 50-day MA of 4.02, and below the 200-day MA of 3.80, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 35.55 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2563.

Beijing Biostar Pharmaceuticals Co., Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

HK:2563 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:8049	80Outperform	HKD 1.48B	4.63	15.91%	―	0.20%	24.13%
HK:2186	58Neutral	HKD 6.36B	8.28	4.40%	―	2.84%	71.92%
HK:6086	58Neutral	HKD 1.45B	148.18	3.67%	―	38.59%	―
HK:2563	57Neutral	HKD 1.36B	-10.19	-16.60%	―	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
HK:1228	39Underperform	HKD 974.29M	-9.09	30.32%	―	-8.00%	51.26%

* General Sector Average

Performance Comparison

HK:2563 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:2563	Beijing Biostar Pharmaceuticals Co., Ltd. Class H	3.50	0.40	12.90%
HK:2186	Luye Pharma Group	1.69	-1.36	-44.59%
HK:8049	Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H	2.73	0.82	42.67%
HK:1228	CANbridge Pharmaceuticals Inc.	1.69	-0.13	-6.91%
HK:6086	Fangzhou Inc.	1.04	-2.02	-65.96%
HK:2566	Hangzhou Jiuyuan Gene Engineering Co Ltd Class H	4.71	-2.70	-36.41%

Beijing Biostar Pharmaceuticals Co., Ltd. Class H Corporate Events

Beijing Biostar Advances Oral Utidelone to Phase III in HER2-Negative Breast Cancer

Oct 20, 2026

Beijing Biostar Pharmaceuticals has reached a key milestone in its oncology pipeline, with its oral Utidelone Capsule (UTD2) initiating first patient dosing in a Phase III trial for HER2-negative advanced breast cancer. The pivotal registration study...

Beijing Biostar Pharmaceuticals Doubles Revenue and Narrows Losses in First Half of 2026

Aug 26, 2026

Beijing Biostar Pharmaceuticals reported a sharp improvement in interim financial performance for the six months ended June 30, 2026, with revenue rising 147.8% year-on-year to RMB36.6 million and gross profit increasing at a similar pace. Despite th...

Beijing Biostar Pharmaceuticals Sets Board Meeting to Review Interim Results and Dividend

Aug 12, 2026

Beijing Biostar Pharmaceuticals has scheduled a board meeting for 26 August 2026 to review its consolidated interim results for the six months ended 30 June 2026 and to consider their publication. The meeting will also discuss whether to recommend an...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026

Beijing Biostar Pharmaceuticals Co., Ltd. Class H AI Stock Analysis